Altimmune nabs additional funding for anthrax vaccine development; shares up 13% premarket

The U.S. Biomedical Advanced Research and Development Authority (BARDA) has awarded an additional $3.7M to Altimmune (NASDAQ:ALT) to support the continued development of its anthrax vaccine. The increase in funding will be primarily used to support a Phase 1b clinical trial of NasoShield to assess alternative methods of intranasal dosing.

BARDA initially awarded the company $2.5M in 2018 to advance NasoShield development.

Shares are up 13% premarket on light volume.


READ  Britain's crucial services sector confounds gloomy forecasts to register growth in February


Please enter your comment!
Please enter your name here